Replies to post #108600 on Avid Bioservices Inc (CDMO)

[freethemice]

This so called rule is totally meaningless. There must have been hundreds of phase III cancer trials over the past 10 years, and yet they pick out 58 to include in their "rule". What about the rest of them? What would the statistics be if they included more than 58, or all of them? Sounds to me like they picked out the 58 so that their "rule" was sure to be "proved". Could there be bias involved here?

[BioBS2012]

Feuerstein Ratain Rule states "after looking at outcomes of 58 phase 3 cancer trials over the past 10 years the pair found the companies with market caps less than $300 milliom several months before the release of trial results were 0-21. Whereas companies with a market cap exceeding $1 billion were a respectable 21-27. Ouch!"

Humm upon further review I would like to mention that the current market cap of PPHM is $282.31 million. So if PPHM share price were to rise just $.15 and hold above there let's just say $2.30, would this negate the rule and give Messers Feuerstein and Ratain their out should PPHM get their partner? We would afterall have a market cap above $300 million. Just asking.

That rule applies to results of Phase III trials NOT Phase II. By the time PPHM's Phase III results are out their valuation would be well north of $1 BILLION !!!!

GLTA